Fresenius nears definitive deal to divest hemodialysis concentrate plant to Di-Chem under FTC pact.
This article was originally published in The Gray Sheet
Executive Summary
FRESENIUS TO DIVEST HEMODIALYSIS CONCENTRATE PLANT TO DI-CHEM under a consent agreement with the Federal Trade Commission finalized Oct. 15. A definitive agreement for the Fresenius/Di-Chem transaction, for undisclosed terms, was said to be moving toward finalization the week of Nov. 4. The deal was outlined in a letter of intent agreement in May to resolve FTC antitrust concerns stemming from Fresenius' proposed acquisition of W.R. Grace dialysis unit National Medical Care.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.